The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy
- PMID: 16217558
The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy
Abstract
The mammalian target of rapamycin (mTOR) is a kinase responsible for mitogen-induced cell proliferation/survival signaling. Its activation in response to mitogens leads to a cell-cycle progression from G1 to S phase. mTOR controls the activation of ribosomal protein translation and the initiation of cap-dependent translation. A role of mTOR signaling pathway dysregulation in tumourigenesis is postulated. mTOR and pathways upstream of this kinase were found to be frequently upregulated in neoplastic diseases. Therefore, it is also an attractive target for antitumour therapy. Several mTOR inhibitors were developed, including rapamycin and its analogues: CCI-779, RAD001 and AP23573. After promising phase I studies, their potential clinical significance is currently under evaluation in several phase II-III trials on patients with solid tumours and some hematological malignancies.
Similar articles
-
Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.Semin Oncol. 2009 Dec;36 Suppl 3:S3-S17. doi: 10.1053/j.seminoncol.2009.10.011. Semin Oncol. 2009. PMID: 19963098 Review.
-
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.Oncogene. 2000 Dec 27;19(56):6680-6. doi: 10.1038/sj.onc.1204091. Oncogene. 2000. PMID: 11426655 Review.
-
Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.J BUON. 2006 Jul-Sep;11(3):267-76. J BUON. 2006. PMID: 17309148 Review.
-
The biology behind mTOR inhibition in sarcoma.Oncologist. 2007 Aug;12(8):1007-18. doi: 10.1634/theoncologist.12-8-1007. Oncologist. 2007. PMID: 17766661 Review.
-
Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.Clin Cancer Res. 2003 Aug 1;9(8):2887-92. Clin Cancer Res. 2003. PMID: 12912932
Cited by
-
Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?Oncologist. 2012;17(8):1051-62. doi: 10.1634/theoncologist.2012-0038. Epub 2012 Jul 17. Oncologist. 2012. PMID: 22807514 Free PMC article. Review.
-
The expression of mammalian target of rapamycin in Ishikawa and HEC-1A cells.J Huazhong Univ Sci Technolog Med Sci. 2008 Jun;28(3):340-2. doi: 10.1007/s11596-008-0325-0. Epub 2008 Jun 19. J Huazhong Univ Sci Technolog Med Sci. 2008. PMID: 18563337
-
Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines.Mol Cancer Ther. 2008 Jun;7(6):1506-13. doi: 10.1158/1535-7163.MCT-07-2334. Mol Cancer Ther. 2008. PMID: 18566221 Free PMC article.
-
The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention.Mol Cancer. 2007 Apr 2;6:24. doi: 10.1186/1476-4598-6-24. Mol Cancer. 2007. PMID: 17407548 Free PMC article. Review.
-
Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2.Med Oncol. 2010 Sep;27(3):592-9. doi: 10.1007/s12032-009-9254-4. Epub 2009 Jun 16. Med Oncol. 2010. PMID: 19533419
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
